Viehbacher On Boston Pharmaceuticals: A New Model To De-Risk Drugs

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.

Gurnet Point Capital, the $2bn health care and life science investment firm that recruited former Sanofi CEO Christopher Viehbacher earlier this year, has committed $600m to one of Viehbacher's pet projects: a company called Boston Pharmaceuticals that will bridge the valley of death between promising early-stage drugs and big pharma's aversion to research and development risk.

"We can green up that valley of death," Viehbacher said in an interview with Scrip. Boston Pharmaceuticals was established with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains